CKD Bio Corp.
Financials
Valuation Metrics
CKD Bio Corp.'s Market Cap is ₩670B. At end of 2025 it was ₩1116B. Ranked #1485 of 2,410 in KR market (top 62%), #632 of 779 on KOSPI (top 81%), #162 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 66.98B KRW | KR#1,485/2,410 Sec#162/231 |
| Revenue | 158.12B KRW | KR#1,145/2,410 Sec#69/231 |
| Net Income | -10.74B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 293.05B KRW | KR#1,053/2,410 Sec#71/231 |
| Net Assets | 119.57B KRW | KR#1,290/2,410 Sec#99/231 |
| Employees | 509 | KR#489/2,410 Sec#41/231 |
| Value | ||
| P/B | 0.56x | KR#1,003/2,410 Sec#55/231 |
| P/S | 0.42x | KR#877/2,410 Sec#35/231 |
| FCF Yield | -16.34% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -8.98% | KR#1,916/2,410 Sec#142/231 |
| ROA | -3.67% | KR#1,865/2,410 Sec#132/231 |
| Op. Margin | -5.10% | KR#1,854/2,410 Sec#124/231 |
| Revenue Growth | -0.58% | KR#1,555/2,410 Sec#155/231 |
| Earnings Growth | -669.88% | KR#1,309/2,410 Sec#92/231 |
| Financial Health | ||
| Debt Ratio | 145.09% | KR#1,869/2,410 Sec#206/231 |
| Total Debt | 146.35B KRW | KR#611/2,410 Sec#35/231 |
| FCF | -10.95B KRW | KR#1,730/2,410 Sec#154/231 |
| Cash | 517.3M KRW | KR#2,354/2,410 Sec#224/231 |
| Current Ratio | 1.06x | KR#1,653/2,410 Sec#165/231 |
| Dividend | ||
| Div. Yield | 1.63% | KR#1,012/2,410 Sec#55/231 |
| Div. Growth | -0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -43.56% | KR#1,778/2,410 Sec#155/231 |
| 1M Return | -4.69% | KR#545/2,410 Sec#59/231 |
| From 52W High | -51.04% | KR#1,171/2,410 Sec#94/231 |
| 1Y MDD | -46.81% | KR#814/2,410 Sec#63/231 |
| Trading | ||
| Volume | 3,625 shares | KR#2,208/2,410 Sec#219/231 |
| Trading Value | 43.6M KRW | KR#1,887/2,410 Sec#198/231 |
| Foreign Own. | 1.43% | KR#1,844/2,410 Sec#183/231 |
| Per Share | ||
| EPS | -1,958 KRW | KR—/2,410 Sec—/231 |
| BPS | 21,796 KRW | KR#500/2,410 Sec#36/231 |
Company Info
Chong Kun Dang Bio was established in 2001 through a spin-off of the fermentation and refined raw materials business. It supplies over 30 types of active pharmaceutical ingredients (APIs), including antibiotics, to over 50 countries worldwide using advanced fermentation facilities. The company produces probiotic raw materials and finished products with its fermentation and patented technologies, and has launched botulinum toxin products from a dedicated plant in Osong. Chong Kun Dang Bio is focusing on obtaining patents for regulatory market entry, achieving cGMP certification for key products, building microbiome CDMO facilities, and developing new drugs for conditions such as Alzheimer's. Chong Kun Dang Bio was established in 2001 and is headquartered in Seodaemun-gu, Seoul.